Homburger

Homburger acted as counsel to UBS Switzerland AG in its capacity as Coordinating Bookrunning Mandated Lead Arranger, Original Lender and Agent in connection with BACHEM HOLDING AG’s new CHF 500 m revolving credit facility agreement. Homburger advised UBS Switzerland AG as well as the other syndicate banks with regard to all legal aspects of the financing transaction. The Homburger team was led by Daniel Haeberli and Stefan Bindschedler (both Financing) and included Yulia Shaburnykova (Financing) as well as Stefan Oesterhelt (Tax). Contact Wanda Schweda / Marketing / [email protected]

On March 31, 2026, Marriott International (Nasdaq: MAR) and the Leali family, founders of Lefay, announced their plans to enter into a joint venture to bring the highly awarded luxury wellness hospitality brand Lefay into the Marriott portfolio. Completion of the transaction is subject to customary approvals and closing conditions. Lefay will be the first brand in Marriott’s portfolio dedicated exclusively to luxury wellness. The Lefay portfolio includes two award-winning luxury resorts in Italy (Lago di Garda and Dolomiti), and a further three properties are under development in Tuscany, Southern Italy, and the Swiss Alps. The Homburger team advising Marriott on all Swiss law aspects of the transaction comprises Margrit Marti, Tobias Gloor and Florian Gasche (all Corporate / M&A) as well as Reto Heuberger, Arbnor Sheholli and Alessandra Dumitru (all Tax). Contact Wanda Schweda / Marketing / [email protected]

On March 16, 2026, UBS AG, acting through its Stamford branch, successfully completed its issuance of (i) USD 500 m in aggregate principal amount of Floating Rate Senior Notes due 2029, (ii) USD 1.3 bn in aggregate principal amount of 4.302 per cent.  Senior Notes due 2029 and (iii) USD 1.25 bn in aggregate principal amount of 4.632 per cent. Senior Notes due 2032 under its medium-term notes program. The notes were offered and sold in reliance on (i) an exemption from registration provided by Section 3(a)(2) of the U.S. Securities Act of 1933, as amended, and (ii) Section 16.6 of Part 16 of the regulations of the Office of the Comptroller of the Currency. The Homburger team was led by Stefan Kramer and Benedikt Maurenbrecher and included Lee Saladino and Daniel Hulmann (all Capital Markets) as well as Stefan Oesterhelt (Tax). Contact Wanda Schweda / Marketing / [email protected]

On March 25, 2026, Liechtensteinisches Pfandbriefinstitut AG established a program for the issuance of Liechtensteiner Pfandbriefe issued by Liechtensteinisches Pfandbriefinstitut AG, with UBS AG, LGT Bank AG and Liechtensteinische Landesbank AG acting as dealers under the program. The Liechtensteiner Pfandbriefe issued under the program will be indirectly backed by a portfolio of mortgages in accordance with the Liechtenstein Pfandbrief Act. On April 24, 2026, Liechtensteinisches Pfandbriefinstitut AG completed its inaugural issuance of Liechtensteiner Pfandbriefe under the program in an aggregate principal amount of CHF 250 m, consisting of CHF 150 m 0.65% Liechtensteiner Pfandbriefe due 2031 and CHF 100 m 0.90% Liechtensteiner Pfandbriefe due 2036. The Liechtensteiner Pfandbriefe are governed by Swiss law, have been assigned a ʻAaaʼ rating by Moody’s and will be listed on the SIX Swiss Exchange. UBS AG acted as Sole Bookrunner and Joint Lead Manager and LGT Bank AG and Liechtensteinische Landesbank AG acted as Joint Lead Managers. The Homburger team was led by Stefan Kramer (Capital Markets) and included Daniel Hulmann, Olivier Baum and Yulia Shaburnykova (all Capital Markets) as well as Stefan Oesterhelt (Tax). Contact Wanda Schweda / Marketing / [email protected]

On April 16, 2026, EFG International Finance (Luxembourg) S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of Luxembourg, issued EUR 500 m 3.925% Guaranteed Bonds 2026 – 2031. The bonds are guaranteed by EFG International AG. The bonds and the guarantee as well as the transaction agreements are governed by Swiss law. UBS AG, London Branch, BofA Securities Europe SA and J.P. Morgan Securities plc acted as Joint Lead Managers. The Homburger team was led by Benjamin Leisinger and Eduard de Zordi (both Capital Markets). Contact Wanda Schweda / Marketing / [email protected]

On March 23, 2026, Swiss-based Kandou AI, a leader in high-speed, energy-efficient connectivity and system solutions for the AI era, announced the successful closing of its USD 225 m strategic funding round with backing from strong financial and strategic investors. The oversubscribed Series-A round was led by Maverick Silicon with strategic participation from SoftBank Group Corp., Synopsys, Inc., Cadence Design Systems, Inc. and Alchip Technologies Limited; several existing investors also participated in the financing round. The Homburger team advising Kandou AI on all aspects of this transaction comprised Andreas Müller, Anna Peter, Luca Ellenberger, Oriana Schöni, Luca Yousef and Filippo Moggi (all Corporate / M&A), Stefan Oesterhelt and Juliette Buob (both Tax), Stefan Bindschedler, Alexander Wherlock and Sara D’Antoni (all Financing), Luca Dal Molin and Joel Fink (both IP/IT, Data Protection) as well as Angela Casey (Employment and Executive Compensation). Contact Wanda Schweda / Marketing / [email protected]

Homburger advised funds managed by Apollo Capital Management L.P. (Apollo Funds) on their strategic minority investment into vVARDIS Holding AG, a high-growth Swiss dental medtech company focused on non-invasive treatment solutions. The investment from Apollo Funds will support vVARDIS’ continued international expansion and the further development and commercialization of its product portfolio, building on prior funding that has accelerated the global rollout of its technologies. vVARDIS announced the investment alongside achieving unicorn status, marking a significant milestone in the company’s growth trajectory and underscoring strong investor confidence in its innovative technology and global expansion strategy. The Homburger team was led by Daniel Hasler (Corporate / M&A) and included Margrit Marti, Anna Peter, Marco Rostetter and Jonas Stähli (all Corporate / M&A) as well as Gregor Bühler and Vanessa Huber (both IP / IT).   Contact Nanding Susso / Marketing / [email protected]

On May 4, 2026, 908 Devices Inc. (NASDAQ: MASS) announced the completion of its acquisition of Swiss-based NIRLAB SA for a combination of cash and stock, including earn-out consideration. The NIRLAB Group develops near-infrared (NIR) spectroscopy solutions for instant material identification. 908 Devices is revolutionizing chemical analysis with its simple handheld devices for vital health, safety, and defense tech applications, such as the illicit drug crisis, toxic carcinogen exposure, and global security threats. The Homburger team advising 908 Devices Inc. comprised Andreas Müller, Olivier Bühlmann, Carlo Sulser, Luca Yousef, Fabia Starkermann and Géraldine Bär (all Corporate / M&A), Luca Dal Molin and Berem Brun (both IP / IT), Reto Heuberger and Juliette Buob (both Tax), Angela Casey (Employment and Executive Compensation), and Richard Stäuber, Allegra Arnold and Giulia Meier (all Competition).   Contact Nanding Susso / Marketing / [email protected]

On March 18, 2026, Nestlé Capital Corporation successfully completed its issuance of (i) USD 750 m in aggregate principal amount of 4.200% Notes due 2031, (ii) USD 500 m in aggregate principal amount of 4.500% Notes due 2033, and (iii) USD 750 m in aggregate principal amount of 4.800% Notes due 2036. The Notes are guaranteed by the Nestlé group’s Swiss parent company Nestlé S.A. The offering of the Notes was done in reliance on Rule 144A and Regulation S under the U.S. Securities Act. Homburger advised Nestlé on all Swiss law aspects of the transaction. The Homburger team was led by Lee Saladino (Capital Markets) and included Daniel Daeniker (Corporate / M&A) and Dieter Grünblatt (Tax).   Contact Wanda Schweda / Marketing / [email protected]

On May 1, 2026, Siegfried Holding AG, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, closed the acquisition of three drug substances sites in the US and Australia from an affiliate of SK Capital Partners. Homburger acted as counsel to Siegfried Holding AG in connection with a Swiss law-governed bridge term facility agreement with UBS Switzerland AG as mandated lead arranger and lender. The Homburger team was led by Jürg Frick (Financing) and included Stefan Bindschedler (Financing) as well as Stefan Oesterhelt (Tax).

On February 23, 2026, Health & Wellness Partners (HWP Group), a leading medical communications and strategic partner to the life sciences industry, has announced the acquisition of Global Market Access Solutions (GMAS), a market access and health economics consultancy with global operations. The Homburger team advising HWP Group comprised Andreas Müller, Carlo Sulser, Magdalena Stock and Fabia Starkermann (all Corporate / M&A), Luca Dal Molin, Angelika Krull and Noëmie Beck-Schär (all IP / IT), Angela Casey (Employment and Executive Compensation) and Laetitia Fracheboud (Tax). Contact Wanda Schweda / Marketing / [email protected]

March 23 2026 AECOM acquired Consigli, a leading Norwegian AI company transforming engineering and early-stage project design. The Homburger team advising AECOM on this transaction comprised Andreas Müller, Luca Ellenberger and Thierry Burckhardt (all Corporate / M&A), Laetitia Fracheboud (Tax), Luca Dal Molin and Joel Fink (both IP / IT) as well as Allegra Arnold (Competition).     Contact Wanda Schweda / Marketing / [email protected]

On April 10, 2026, Mondelēz International, Inc., successfully placed bonds in Switzerland in the aggregate amount of CHF 850 m. The CHF offering was comprised of CHF 325 m aggregate principal amount of 0.9575% senior notes due 2029, CHF 245 m aggregate principal amount of 1.2713% senior notes due 2032 and CHF 280 m aggregate principal amount of 1.6250% senior notes due 2036. Deutsche Bank AG London Branch, acting through Deutsche Bank AG Zurich Branch, is acting as representative of the managers for the CHF offering, which include BNP PARIBAS, Paris, Lancy/Geneva Branch, Goldman Sachs International and Commerzbank Aktiengesellschaft. The Homburger team was led by Benjamin Leisinger and Eduard de Zordi (both Capital Markets).   Contact Wanda Schweda / Marketing / [email protected]

On March 2, 2026, Novartis AG (SIX: NOVN / NYSE: NVS), acting through one of its wholly-owned indirect subsidiaries, completed the acquisition of Avidity Biosciences, Inc. (NASDAQ: RNAM), pursuant to the terms of the merger agreement for a total value of approximately USD 12 bn. Homburger advised Novartis AG and its subsidiaries with respect to all Swiss law aspects of the acquisition of Avidity Biosciences, Inc. The Homburger team was led by Frank Gerhard (Corporate / M&A) and Benjamin Leisinger (Capital Markets) and included Stefan Bindschedler (Financing), Olivier Baum (Capital Markets, Corporate / M&A) as well as Timo Hasler (Corporate / M&A). Contact Wanda Schweda / Marketing / [email protected]

On March 10, 2026, a consortium led by EQT, consisting of Sunshine SwissCo GmbH, the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as the Sellers), announced the launch of an accelerated bookbuilding process to professional investors in Switzerland and to qualified investors outside Switzerland, which led to the successful placement of ca. 34 m shares in Galderma Group AG corresponding to ca. 14.3% of its share capital at a price of CHF 143.75 per share (the Placement), raising ca. CHF 4.9 bn in total. Following the Placement, the Selling Shareholders have fully exited their investment in Galderma. The Placement thus marks the conclusion of a journey that began with the Selling Shareholders’ acquisition of Galderma in 2019, followed by the Company’s landmark 2024 IPO on SIX Swiss Exchange and continued through a series of successful post IPO sell downs in 2024, 2025 and 2026. Thus, including the IPO, the seven sell-downs in the market by way of accelerated bookbuildings and the two transactions with L’Oréal, the Selling Shareholders have sold Galderma shares for a total amount of ca. CHF 19 bn. As communicated by Galderma on December 8, 2025 in the context of the increased equity investment from L’Oréal, the board members representing the consortium led by EQT will not stand for re-election at the 2026 Annual General Meeting. The Placement is expected to be settled on March 13, 2026. Citigroup Global Markets Limited, Goldman Sachs International, Jefferies GmbH, J.P. Morgan Securities plc, Morgan Stanley & Co. International plc and UBS AG are acting as Joint Global Coordinators and Joint Bookrunners in the Placement. Homburger acted as transaction counsel to EQT. The Homburger team was led by Frank Gerhard and Margrit Marti and included Estelle Piccard and Luca Yousef (all Corporate / M&A, Capital Markets). Contact Wanda Schweda / Marketing / [email protected]

On March 6, 2026, Roche Holding AG, Roche Holdings, Inc. and Roche Finanz AG entered into a Swiss law governed USD 7.5 bn revolving credit facility agreement arranged by and syndicated among twelve international banks, coordinated by Deutsche Bank. The Homburger team was led by Jürg Frick and Stefan Bindschedler and included Samuel Fäh and Yulia Shaburnykova (all Financing, Investment Products) as well as Stefan Oesterhelt (Tax).   Contact Wanda Schweda / Marketing / [email protected]

On February 2, 2026, Element Solutions Inc (NYSE: ESI), a global and diversified specialty chemicals technology company, announced that it has completed its previously announced acquisition of Micromax from Celanese Corporation (NYSE: CE) for approximately USD 500 m in cash. Micromax is a leading global supplier of advanced electronic inks and pastes designed for high‑performance electronics and known for their durability, flexibility and performance in harsh environments. The Homburger team advising Element Solutions on all Swiss law aspects of the transaction comprised Andreas Müller and Caspar Wehrle (both Corporate / M&A), Angela Casey (Employment and Executive Compensation), Philippe Gobet, Miriam Kämpf and Philippe Weber (all Tax) as well as Luca Dal Molin (Data Protection). Contact Wanda Schweda / Marketing / [email protected]

On February 23, 2026, ADC Therapeutics SA (NYSE: ADCT) announced that it had amended its royalty purchase agreement with entities managed by HealthCare Royalty. As consideration for reducing change of control payment from USD 750 m to USD 150 m to USD 200 m, HealthCare Royalty has received warrants to purchase approximately 9.8 m common shares of ADC Therapeutics at an exercise price of USD 3.81 per share. Homburger advised ADC Therapeutics on the Swiss law aspects of the transaction. The Homburger team was led by Daniel Häusermann and included Estelle Piccard and Anina Preusker (all Corporate / M&A, Capital Markets).     Contact Wanda Schweda / Marketing / [email protected]

On February 18, 2026, the State of North Rhine-Westphalia successfully completed its issuance of (i) CHF 100 m in aggregate principal amount of 0.3675 per cent. State Treasury Notes due February 18, 2031, (ii) CHF 175 m in aggregate principal amount of 0.7700 per cent. State Treasury Notes due February 18, 2036, and (iii) CHF 190 m in aggregate principal amount of 1.0650 per cent.  State Treasury Notes due February 18, 2044 under its Debt Issuance Programme. The State Treasury Notes are governed by German law, and the State Treasury Notes have been provisionally admitted to trading, and application has been made for definitive admission to trading and listing of the Notes, on the SIX Swiss Exchange. Homburger advised Raiffeisen Schweiz Genossenschaft with respect to all regulatory and transactional aspects of Swiss law. The Homburger team was led by Benjamin Leisinger (Capital Markets) and included Sofiya Shavlak (Capital Markets) as well as Stefan Oesterhelt (Tax). Contact Wanda Schweda / Marketing / [email protected]

On March 2, 2026, Zurich Insurance Group Ltd (SIX: ZURN) announced the launch of an accelerated bookbuilding offering, which led to the successful placement of 7,090,909 newly issued shares at an offer price of CHF 550 per offered share, raising aggregate gross proceeds of approximately CHF 3.9 bn. Zurich intends to use the net proceeds from the capital increase to partly finance the acquisition of Beazley plc. The offering was conducted by way of (i) a placement to professional investors in Switzerland or in any other circumstances relying on an exemption from the obligation to publish a prospectus under the Swiss Financial Services Act, (ii) private placements in certain jurisdictions outside of Switzerland and the United States, and (iii) private placements within the United States to qualified institutional buyers in reliance on Rule 144A under the U.S. Securities Act. Goldman Sachs, Morgan Stanley and UBS acted as Joint Global Coordinators and Bookrunners, Citigroup and Deutsche Bank acted as Joint Bookrunners as well, and Crédit Agricole and Zürcher Kantonalbank acted as Co-Lead Managers in connection with the offering. Homburger advised Zurich on all aspects of Swiss corporate and capital markets law. The Homburger team was led by Hansjürg Appenzeller (Corporate / M&A, Capital Markets, Insurance) and Lorenzo Togni (Capital Markets) and included Matthias Müller (Corporate / M&A) as well as Fabrice Eckert (Insurance, Financing). Dieter Grünblatt and Arbnor Sheholli provided tax advice. Contact Wanda Schweda / Marketing / [email protected]